Zydus Cadila Gets USFDA Final Nod For Low Blood Pressure Drug Droxidopa

Zydus Cadila on Friday said it has received final approval from the US health regulator to market Droxidopa capsules, used to treat low blood pressure.

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Droxidopa capsules in the strength of 100 mg, 200 mg, and 300 mg, Cadila Healthcare said in a regulatory filing.

Zydus Cadila is part of the Cadila Healthcare group.

Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.

The company further said that Droxidopa is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).

The newly approved medication will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 312 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.

Shares of Cadila Healthcare were trading 1.51 per cent lower at Rs 460.45 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor